Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.57 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962623 | 0.88 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP4Z1TDP1CYP1A2 | |
| SCHEMBL7013456 | 0.81 | CYP11B1 (0.46) | CYP4F2CYP4A11MAPTLMNATBXAS1 | |
| SCHEMBL8863393 | 0.81 | SMN1; SMN2 (0.46) | CYP4F2CYP4A11CYP4Z1L3MBTL1MAPT | |
| SCHEMBL30178455 | 0.81 | CYP4F2 (0.53) | CYP4F2CYP4A11CYP4Z1L3MBTL1MAPT | |
| SCHEMBL3957320 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11L3MBTL1TDP1TBXAS1 | |
| SCHEMBL24623096 | 0.79 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1L3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL27552763 | 0.79 | CYP4F2 (0.54) | CYP4F2CYP4A11L3MBTL1TDP1TBXAS1 | |
| SCHEMBL16838961 | 0.79 | LTA4H (0.42) | CYP4F2CYP4A11MAPTCYP1A2KDM4E | |
| SCHEMBL5883491 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP4Z1MAPTPDE3B | |
| Hydrochloric Acid SCHEMBL18230734 | 0.79 | CYP4F2 (0.54) | CYP4F2CYP4A11L3MBTL1TDP1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| CN-1286822-C | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-11-29 | — | — | CN | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1479671-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040167142-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. | 2004-08-26 | — | — | US | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| CN-1358175-A | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2002-07-10 | — | — | CN | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| US-4305945-A | Isoureas and isothioureas | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-15 | — | — | US | disclosed |
| EP-0003677-B1 | PYRIMIDONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-11-11 | — | — | EP | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| EP-0015138-A1 | Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
| EP-0007232-A1 | Iso(thio)ureas, processes for their preparation and compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-23 | — | — | EP | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | CYP4F2 1389/4885CYP4A11 1009/4885CYP4Z1 1978/4885 |
| US-20040167142-A1 | Pyrimidinone compounds | LPL, LIPG, PCSK9 | CYP4F2 397/4885CYP4A11 1085/4885CYP4Z1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.